The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial
Open accessAbstract
Background Ivacaftor, approved for treatment of cystic fibrosis (CF) patients aged ≥6 years with G551D-CFTR or other gating mutations, was evaluated in subjects with R117H-CFTR, a residual function mutation. Methods A 24 week, placebo-controlled, double-blind, randomized clinical trial (RCT) enrolled 69 CF subjects aged ≥6 years with R117H-CFTR and percent predicted forced expiratory volume in 1 second (ppFEV1) ≥40. Primary outcome was absolute change from baseline in ppFEV1 through week 24. Secondary outcomes included sweat chloride, CF Questionnaire-Revised (CFQ-R) respiratory domain, and safety. An open-label extension enrolled 65 RCT subjects after washout; after 12 weeks, an interim analysis was performed. Findings After 24 weeks, treatment difference in mean absolute change in ppFEV1 between ivacaftor (n=34) and placebo (n=35) was 2.1 percentage points (p=0·20). Ivacaftor treatment resulted in significant RCT treatment differences in sweat chloride (−24.0 mmol/L; p<0.001) and CFQ-R respiratory domain (8.4; p=0.009). In prespecified subgroup analyses, ppFEV1 significantly improved with ivacaftor in subjects aged ≥18 years (treatment difference vs placebo: 5.0 percentage points; p=0.01), but not in subjects aged 6 to 11 years (−6.3 percentage points; p=0.03). In the extension study, both placebo/ivacaftor and ivacaftor/ivacaftor groups showed ppFEV1 improvement (absolute change from postwashout baseline at week 12: 5.5 percentage points; p<0.0001). No new safety concerns were identified. Interpretation Although this RCT did not meet the primary outcome, secondary outcomes and subgroup analyses suggest that ivacaftor significantly improves lung function in adult patients with R117H-CFTR and may benefit patients with established disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citationBobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Quittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009) · Chest · doi:10.1378/chest.08-1190 · Cited by 400
Cited by
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Self-citationECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Self-citationVeit, G., Avramescu, R. G., Chiang, A. N., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0935 · Cited by 580
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522
Self-citationProgress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
Metadata
- Authors
- Moss, R. B., Flume, P. A., Elborn, J. S., Cooke, J., Rowe, S. M., McColley, S. A., Rubenstein, R. C., & Higgins, M.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 3
- Issue
- 7
- Pages
- 524-533
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2133435216
- Cited by
- 228
- References
- 3
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-2600(15)00201-5
- The paper
- Moss, R. B., Flume, P. A., Elborn, J. S., Cooke, J., Rowe, S. M., McColley, S. A., Rubenstein, R. C., & Higgins, M. (2015). Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(15)00201-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.